0001567619-18-002684.txt : 20180914
0001567619-18-002684.hdr.sgml : 20180914
20180914192916
ACCESSION NUMBER: 0001567619-18-002684
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180912
FILED AS OF DATE: 20180914
DATE AS OF CHANGE: 20180914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Templeman Blaine
CENTRAL INDEX KEY: 0001653641
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 181072184
MAIL ADDRESS:
STREET 1: C/O ADURO BIOTECH, INC.
STREET 2: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADURO BIOTECH, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
BUSINESS PHONE: 510-848-4400
MAIL ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc1.xml
FORM 4
X0306
4
2018-09-12
0
0001435049
ADURO BIOTECH, INC.
ADRO
0001653641
Templeman Blaine
C/O ADURO BIOTECH, INC.
740 HEINZ AVENUE
BERKELEY
CA
94710
0
1
0
0
Executive VP, General Counsel
Common Stock
2018-09-12
4
A
0
77500
0.00
A
147437
D
Common Stock
2018-09-13
4
S
0
6056
6.4993
D
141381
D
Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018.
The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Jennifer Lew, Attorney-in-Fact
2018-09-14